1. Home
  2. SWKH vs FATE Comparison

SWKH vs FATE Comparison

Compare SWKH & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWKH
  • FATE
  • Stock Information
  • Founded
  • SWKH 1996
  • FATE 2007
  • Country
  • SWKH United States
  • FATE United States
  • Employees
  • SWKH N/A
  • FATE N/A
  • Industry
  • SWKH Diversified Financial Services
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SWKH Finance
  • FATE Health Care
  • Exchange
  • SWKH Nasdaq
  • FATE Nasdaq
  • Market Cap
  • SWKH 179.1M
  • FATE 177.7M
  • IPO Year
  • SWKH 1999
  • FATE 2013
  • Fundamental
  • Price
  • SWKH $15.04
  • FATE $1.12
  • Analyst Decision
  • SWKH Strong Buy
  • FATE Hold
  • Analyst Count
  • SWKH 1
  • FATE 7
  • Target Price
  • SWKH $18.00
  • FATE $3.83
  • AVG Volume (30 Days)
  • SWKH 17.4K
  • FATE 2.2M
  • Earning Date
  • SWKH 08-14-2025
  • FATE 08-12-2025
  • Dividend Yield
  • SWKH N/A
  • FATE N/A
  • EPS Growth
  • SWKH 51.50
  • FATE N/A
  • EPS
  • SWKH 1.41
  • FATE N/A
  • Revenue
  • SWKH $34,906,000.00
  • FATE $13,335,000.00
  • Revenue This Year
  • SWKH $52.93
  • FATE N/A
  • Revenue Next Year
  • SWKH N/A
  • FATE N/A
  • P/E Ratio
  • SWKH $10.70
  • FATE N/A
  • Revenue Growth
  • SWKH 18.02
  • FATE 105.85
  • 52 Week Low
  • SWKH $12.00
  • FATE $0.66
  • 52 Week High
  • SWKH $16.24
  • FATE $5.92
  • Technical
  • Relative Strength Index (RSI)
  • SWKH 59.21
  • FATE 44.34
  • Support Level
  • SWKH $14.56
  • FATE $1.02
  • Resistance Level
  • SWKH $15.28
  • FATE $1.23
  • Average True Range (ATR)
  • SWKH 0.34
  • FATE 0.11
  • MACD
  • SWKH 0.04
  • FATE -0.03
  • Stochastic Oscillator
  • SWKH 78.57
  • FATE 20.41

About SWKH SWK Holdings Corporation

SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Share on Social Networks: